Cancer risk in long-term users of vitamin K antagonists: A population-based case-control study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Some evidence suggests that long-term use of vitamin K antagonists (VKAs) has a cancer chemopreventive effect. Such an
effect would have considerable implications in terms of understanding tumor biology. To evaluate if long-term VKA treatment
influences the risk of developing cancer, we performed a matched case–control analysis. We used data from four Danish
nationwide registers. Cases were all Danish individuals with a first-time cancer diagnosis (except nonmelanoma skin cancer)
between 2000 and 2009. For each case, eight controls, matched by birth year and gender, were selected from the source
population by risk-set sampling. Long-term VKA use was defined as exposure to VKA for a period of 3 or more years.
Conditional logistic regression was used to compute odds ratios (ORs) for cancer associated with long-term VKA exposure,
adjusting for potential confounders. Prespecified subanalyses were performed for selected cancer sites, subgroups and
measures of exposure. A total of 238,196 cases and 1,713,176 controls were included. The adjusted OR for cancer associated
with long-term VKA exposure was 0.99 (95% CI: 0.95–1.02). Long-term VKA use was associated with increased ORs for
alcohol- or obesity-related cancer sites, whereas we observed a decreased risk of prostate cancer (OR: 0.86; 95% CI:
0.78–0.95). Our study does not support a general chemopreventive effect of VKA drugs. However, in accordance with findings
from previous studies, we found an inverse association between use of VKA and prostate cancer.
OriginalsprogEngelsk
TidsskriftInternational Journal of Cancer
Vol/bind132
Udgave nummer11
Sider (fra-til)2606-2612
ISSN0020-7136
DOI
StatusUdgivet - 2013

Citer dette

@article{039579f143124a90a9a92902be8666d3,
title = "Cancer risk in long-term users of vitamin K antagonists: A population-based case-control study",
abstract = "Some evidence suggests that long-term use of vitamin K antagonists (VKAs) has a cancer chemopreventive effect. Such aneffect would have considerable implications in terms of understanding tumor biology. To evaluate if long-term VKA treatmentinfluences the risk of developing cancer, we performed a matched case–control analysis. We used data from four Danishnationwide registers. Cases were all Danish individuals with a first-time cancer diagnosis (except nonmelanoma skin cancer)between 2000 and 2009. For each case, eight controls, matched by birth year and gender, were selected from the sourcepopulation by risk-set sampling. Long-term VKA use was defined as exposure to VKA for a period of 3 or more years.Conditional logistic regression was used to compute odds ratios (ORs) for cancer associated with long-term VKA exposure,adjusting for potential confounders. Prespecified subanalyses were performed for selected cancer sites, subgroups andmeasures of exposure. A total of 238,196 cases and 1,713,176 controls were included. The adjusted OR for cancer associatedwith long-term VKA exposure was 0.99 (95{\%} CI: 0.95–1.02). Long-term VKA use was associated with increased ORs foralcohol- or obesity-related cancer sites, whereas we observed a decreased risk of prostate cancer (OR: 0.86; 95{\%} CI:0.78–0.95). Our study does not support a general chemopreventive effect of VKA drugs. However, in accordance with findingsfrom previous studies, we found an inverse association between use of VKA and prostate cancer.",
keywords = "cancer, case-control study, pharmacoepidemiology, population based, vitamin K antagonists, Prognosis, Follow-Up Studies, Humans, Middle Aged, Risk Factors, Male, Anticoagulants/adverse effects, Case-Control Studies, Denmark/epidemiology, Female, Aged, Neoplasms/epidemiology, Vitamin K/antagonists & inhibitors",
author = "Anton Potteg{\aa}rd and S{\o}ren Friis and Jesper Hallas",
year = "2013",
doi = "10.1002/ijc.27905",
language = "English",
volume = "132",
pages = "2606--2612",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "JohnWiley & Sons, Inc.",
number = "11",

}

Cancer risk in long-term users of vitamin K antagonists: A population-based case-control study. / Pottegård, Anton; Friis, Søren ; Hallas, Jesper.

I: International Journal of Cancer, Bind 132, Nr. 11, 2013, s. 2606-2612.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Cancer risk in long-term users of vitamin K antagonists: A population-based case-control study

AU - Pottegård, Anton

AU - Friis, Søren

AU - Hallas, Jesper

PY - 2013

Y1 - 2013

N2 - Some evidence suggests that long-term use of vitamin K antagonists (VKAs) has a cancer chemopreventive effect. Such aneffect would have considerable implications in terms of understanding tumor biology. To evaluate if long-term VKA treatmentinfluences the risk of developing cancer, we performed a matched case–control analysis. We used data from four Danishnationwide registers. Cases were all Danish individuals with a first-time cancer diagnosis (except nonmelanoma skin cancer)between 2000 and 2009. For each case, eight controls, matched by birth year and gender, were selected from the sourcepopulation by risk-set sampling. Long-term VKA use was defined as exposure to VKA for a period of 3 or more years.Conditional logistic regression was used to compute odds ratios (ORs) for cancer associated with long-term VKA exposure,adjusting for potential confounders. Prespecified subanalyses were performed for selected cancer sites, subgroups andmeasures of exposure. A total of 238,196 cases and 1,713,176 controls were included. The adjusted OR for cancer associatedwith long-term VKA exposure was 0.99 (95% CI: 0.95–1.02). Long-term VKA use was associated with increased ORs foralcohol- or obesity-related cancer sites, whereas we observed a decreased risk of prostate cancer (OR: 0.86; 95% CI:0.78–0.95). Our study does not support a general chemopreventive effect of VKA drugs. However, in accordance with findingsfrom previous studies, we found an inverse association between use of VKA and prostate cancer.

AB - Some evidence suggests that long-term use of vitamin K antagonists (VKAs) has a cancer chemopreventive effect. Such aneffect would have considerable implications in terms of understanding tumor biology. To evaluate if long-term VKA treatmentinfluences the risk of developing cancer, we performed a matched case–control analysis. We used data from four Danishnationwide registers. Cases were all Danish individuals with a first-time cancer diagnosis (except nonmelanoma skin cancer)between 2000 and 2009. For each case, eight controls, matched by birth year and gender, were selected from the sourcepopulation by risk-set sampling. Long-term VKA use was defined as exposure to VKA for a period of 3 or more years.Conditional logistic regression was used to compute odds ratios (ORs) for cancer associated with long-term VKA exposure,adjusting for potential confounders. Prespecified subanalyses were performed for selected cancer sites, subgroups andmeasures of exposure. A total of 238,196 cases and 1,713,176 controls were included. The adjusted OR for cancer associatedwith long-term VKA exposure was 0.99 (95% CI: 0.95–1.02). Long-term VKA use was associated with increased ORs foralcohol- or obesity-related cancer sites, whereas we observed a decreased risk of prostate cancer (OR: 0.86; 95% CI:0.78–0.95). Our study does not support a general chemopreventive effect of VKA drugs. However, in accordance with findingsfrom previous studies, we found an inverse association between use of VKA and prostate cancer.

KW - cancer

KW - case-control study

KW - pharmacoepidemiology

KW - population based

KW - vitamin K antagonists

KW - Prognosis

KW - Follow-Up Studies

KW - Humans

KW - Middle Aged

KW - Risk Factors

KW - Male

KW - Anticoagulants/adverse effects

KW - Case-Control Studies

KW - Denmark/epidemiology

KW - Female

KW - Aged

KW - Neoplasms/epidemiology

KW - Vitamin K/antagonists & inhibitors

U2 - 10.1002/ijc.27905

DO - 10.1002/ijc.27905

M3 - Journal article

C2 - 23065946

VL - 132

SP - 2606

EP - 2612

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 11

ER -